For the first time, advertisements for one brand of snus can say that using the smokeless tobacco product 'instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.'
For the first time, advertisements for one brand of snus can say that using the smokeless tobacco product"instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis."
The US Food and Drug Administration announced on Tuesday it was allowing the marketing through the modified risk tobacco product pathway. It's the first time the agency has allowed product marketing of this type.'Emerging' tobacco products gaining traction among young, CDC survey findsWhat that means is that there are now eight Swedish Match USA Inc.
"Although there are obvious distinctions between e-cigarettes like JUUL and smokeless tobacco products like General snus, the fact that another kind of highly-addictive 'reduced risk' product is proving so appealing to young people, in part because it can be used discreetly, should cause FDA to closely scrutinize the potential impact of modified risk claims for General snus on youth initiation," the letter to the FDA said.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
FDA approves AstraZeneca diabetes drug for treating heart failure riskAstraZeneca's diabetes drug Farxiga has been approved for use in the United...
Lire la suite »
Recall: FDA Sees Trace Asbestos in J&J Baby PowderJohnson & Johnson said FDA testing as recently as last month found no trace of asbestos. The company says the FDA's most recent test found 'sub-trace levels' of asbestos in samples from a single bottle.
Lire la suite »
FDA OKs Diabetes Drug for Type 2 Heart Failure RiskThe FDA granted a new use for diabetes drug Farxiga (dapagliflozin): to reduce the risk of hospitalization for heart failure in adults who have type 2 diabetes and established heart disease or risk factors for it.
Lire la suite »
FDA approves new breakthrough therapy for cystic fibrosisToday's US_FDA approval, makes treatment available to 90% of cystic fibrosis patients 12 & older – some who previously had no options – and giving others in the community access to an additional effective therapy.
Lire la suite »
Biogen, in Reversal, Will Seek FDA OK for Alzheimer’s Drug After Further AnalysisBiogen said it plans to pursue regulatory approval for aducanumab, an investigational treatment for early Alzheimer’s disease, after pulling the plug on phase 3 studies of the drug earlier this year.
Lire la suite »
FDA Approves New Drug for Most Common Form of Cystic FibrosisActing FDA Commissioner Dr. Ned Sharpless said the approval was an outgrowth of efforts to speed development of new therapies for complex diseases.
Lire la suite »